Comparison · NCT03032965-6b310784
Adenosine and Isoproterenol vs Isoproterenol: Number of Subjects Who Need Repeat Ablations
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Adenosine and Isoproterenol vs Isoproterenol: Number of Subjects Who Need Repeat Ablations. Trial comparisons, record NCT03032965-6b310784. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03032965-6b310784
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.197 | 0.116 | 0.313 | wilson | |
| Risk in group 2 | 0.132 | 0.0712 | 0.233 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0644 | -0.0643 | 0.196 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.49 | 0.673 | 3.28 | log | |
| Odds ratio, group 1 over group 2 | 1.61 | 0.625 | 4.12 | log | |
| Number needed to treat, for one more participant with the outcome on Adenosine and Isoproterenol than on Isoproterenol | 15.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Adenosine and Isoproterenol | Patients in this group will receive 12-24mg of adenosine for each PV in order to assess dormant PV conduction.~Adenosine: Subject will receive 6-24 mg of intravenous adenosine given rapidly for each PV in order to assess dormant PV conduction.~Subjects in this group will also receive isoproterenol to assess inducibility of AF with re-isolation of PVs and targeting non PV sources of AF if necessary.Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate.~Isoproterenol: Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate. The isoproterenol infusion will be discontinued upon induction of AF, a decrease in systolic blood pressure to\<85 mmHg, complaints of severe chest tightness, electrocardiographic changes suggestive of ischemia, or upon completion of the infusion protocol. | 12 | 61 | OG000 |
| Group 2 | Isoproterenol | This group will not receive adenosine during the procedure.~Isoproterenol: Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate. The isoproterenol infusion will be discontinued upon induction of AF, a decrease in systolic blood pressure to\<85 mmHg, complaints of severe chest tightness, electrocardiographic changes suggestive of ischemia, or upon completion of the infusion protocol. | 9 | 68 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Subjects Who Need Repeat Ablations
- Description
- Number of participants who had one or more repeat ablation procedures due to documented recurrence of Symptomatic AF or atrial flutter/tachycardia.
- Time frame
- date of ablation to 6 months after procedure
- Population
Source ClinicalTrials.gov
Trial
- Title
- Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation
- NCT number
- NCT03032965
- Phases
- PHASE2
- Conditions
- Atrial Fibrillation
- Interventions
- Adenosine, Isoproterenol
- Lead sponsor
- University of Michigan
- Results first posted
- 2017-12-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03032965?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03032965-6b310784